Australia markets open in 8 hours 47 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
293.95-5.28 (-1.76%)
As of 11:13AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close299.23
Open299.89
Bid293.94 x 1000
Ask294.53 x 800
Day's range291.45 - 299.89
52-week range176.36 - 305.95
Volume254,997
Avg. volume1,603,029
Market cap75.386B
Beta (5Y monthly)0.45
PE ratio (TTM)24.09
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the

  • Business Wire

    Vertex Reports Second Quarter 2022 Financial Results

    BOSTON, August 04, 2022--Vertex Reports Second Quarter 2022 Financial Results

  • Business Wire

    Vertex Advances VX-548 in Acute and Neuropathic Pain

    BOSTON, July 22, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the U.S. Food and Drug Administration (FDA), Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in the fourth quarter of 2022. Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the